GILEAD SCIENCES, INC. (GILD) Factsheet
Earnings-call transcript: covered (issuer-published) · IR deck: cataloged — watch a real agent read these end-to-end →
GILEAD SCIENCES, INC. (GILD) Stock Analysis
Analysis from 10-Q filed 2025-11-07. Data as of Q1 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC 19.4%. FCF margin 34.4%. D/E 0.9x. Source: 10-Q filed 2025-11-07.
| Metric | Value | Context |
|---|---|---|
| ROIC | 19.4% | Solid returns |
| FCF Margin | 34.4% | Strong cash generation |
| Debt/Equity | 0.9x | Moderate leverage |
ROIC 19.4% — Top 25% of sector peers. FCF margin 34.4% — Top 5%.
Explore GILEAD SCIENCES, INC.: Earnings History | Filings
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for GILD: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: GILEAD SCIENCES, INC. earns 19.4% ROIC, Top 25% in Healthcare
ROIC TTM 19.4%, sector median -6.0%, Top 25%. DuPont: NOPAT margin 30.0% × asset turnover 0.5x. Gross margin 79.4%. Operating margin 34.9%. Source: 10-Q filed 2025-11-07.
| Metric | GILD | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 19.4% | Good | Above sector median of -6.0% |
| Return on Equity (ROE) | 43.2% | Excellent | Efficient use of shareholder equity |
| Gross Margin | 79.4% | Excellent | Strong pricing power |
| Operating Margin | 34.9% | Excellent | Efficient operations |
Cash Flow: GILEAD SCIENCES, INC. generates $10.2B FCF at 34.4% margin, positive NaN/8 quarters
FCF TTM $10.2B. FCF margin 34.4%, Top 5%. OCF/Net income 1.2x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-11-07.
| Metric | GILD | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 34.4% | Excellent | Excellent cash conversion |
| Free Cash Flow (TTM) | $10.2B | Good | Positive cash generation |
| OCF/Net Income | 1.2x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: GILEAD SCIENCES, INC. at 0.9x leverage
Debt/Equity 0.9x. Total debt $22.2B, cash & investments $7.6B. Source: 10-Q filed 2025-11-07.
| Metric | GILD | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.9x | Adequate | Moderate leverage |
| Net Cash Position | $-14.5B | Warning | Net debt position |
Valuation: GILEAD SCIENCES, INC. trades at 18.8x earnings
P/E 18.8x. EV/Sales 5.5x. FCF yield 5.9%. Dividend yield 2.3%. Source: 10-Q filed 2025-11-07.
| Metric | GILD | Rating | Context |
|---|---|---|---|
| P/E Ratio | 18.8x | Adequate | Reasonable valuation |
| EV/Sales | 5.5x | Adequate | Growth premium priced in |
| FCF Yield | 5.9% | Good | Attractive cash return |
| Dividend Yield | 2.3% | Adequate | Growth focus over income |
Capital Allocation: GILEAD SCIENCES, INC. returns 3.3% shareholder yield
Total shareholder yield 3.3% (div 2.3% + buyback 0.9%). Capital returned $5.6B TTM. Source: 10-Q filed 2025-11-07.
| Metric | GILD | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 3.3% | Good | Dividend + buyback yield combined |
| Buyback Yield | 0.9% | Adequate | Minimal buyback activity |
| Total Capital Returned (TTM) | $5.6B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 19.4% | Top 25% | - |
| Free Cash Flow Margin | 34.4% | Top 5% | - |
| Gross Margin | 79.4% | Top 25% | 1.2x above |
| Operating Margin | 34.9% | Top 10% | 45.1x above |
| Return on Equity (ROE) | 43.2% | Top 25% | - |
| P/E Ratio | 18.8x | N/A | - |
Financial Scorecard
| Metric | GILD | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 19.4% | Good | Top 25% of sector (median: -6.0%) |
| Free Cash Flow Margin | 34.4% | Excellent | Top 5% of sector (median: 0.0%) |
| Gross Margin | 79.4% | Excellent | Top 25% of sector (median: 63.9%) |
| Debt to Equity Ratio | 94.3% | Adequate | Elevated but manageable |
| P/E Ratio (Price-to-Earnings) | 18.8x | Adequate | Fair value |
| Free Cash Flow Yield | 5.9% | Good | Solid cash yield |
Frequently Asked Questions
Q: What is GILEAD SCIENCES, INC.'s Return on Invested Capital (ROIC)?
GILEAD SCIENCES, INC. (GILD) has a trailing twelve-month Return on Invested Capital (ROIC) of 19.4%. Sector median -6.0%. Source: 10-Q filed 2025-11-07.
Q: What is GILEAD SCIENCES, INC.'s Free Cash Flow Margin?
GILEAD SCIENCES, INC. (GILD) has a free cash flow margin of 34.4%, generating $10.2 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-11-07.
Q: What is GILEAD SCIENCES, INC.'s P/E ratio and how does it compare to peers?
GILEAD SCIENCES, INC. (GILD) trades at a P/E ratio of 18.8x, which is above the sector median of N/A. EV/Sales 5.5x. FCF yield 5.9%. Source: 10-Q filed 2025-11-07.
Q: Does GILEAD SCIENCES, INC. pay a dividend?
GILEAD SCIENCES, INC. (GILD) currently pays a dividend yield of 2.3%. Total shareholder yield (dividend + buybacks) 3.3%. Source: 10-Q filed 2025-11-07.
Q: How much debt does GILEAD SCIENCES, INC. have?
GILEAD SCIENCES, INC. (GILD) has a debt-to-equity ratio of 0.9x with total debt of $22.2 billion. Net debt $14.5 billion. Source: 10-Q filed 2025-11-07.
Q: What is GILEAD SCIENCES, INC.'s revenue and earnings growth?
GILEAD SCIENCES, INC. (GILD) grew revenue by 3.5% year-over-year. EPS +55.4% YoY. Source: 10-Q filed 2025-11-07.
Q: Is GILEAD SCIENCES, INC. buying back stock?
GILEAD SCIENCES, INC. (GILD) repurchased $1.6 billion of stock over the trailing twelve months. This represents a buyback yield of 0.9%. Source: 10-Q filed 2025-11-07.
Q: How does GILEAD SCIENCES, INC. compare to competitors in Healthcare?
Compared to other companies in Healthcare, GILEAD SCIENCES, INC. (GILD) shows: ROIC 19.4%, sector median -6.0% (Top 25%). FCF margin 34.4%, sector median 0.0% (Top 5%). Gross margin 79.4%, 15.5pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with GILEAD SCIENCES, INC.?
No quantitative warning flags fired for GILEAD SCIENCES, INC. (GILD) on margin trend, FCF trend, ROIC trend, or leverage thresholds. Source: 10-Q filed 2025-11-07.
Data Source: Data sourced from 10-Q filed 2025-11-07. TTM metrics as of Q1 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.